PuraStat’s core technology is derived from self-assembling peptides (SAPs). The discovery of SAP technology by a Massachusetts Institute of Technology (MIT) post-doctoral researcher led to a completely new field of peptide biotechnology. Research found that this new technology could be used in areas including tissue engineering, 3D tissue cell culture, and surgical and clinical applications.

PuraStat™ Advantages

- **Highly suitable for RP**: A safe, effective and non-toxic modality, which reduces the need for thermal techniques
- **Synthetic peptide technology**: An inert hydrogel that contains no animal/plant derivatives and mimics the human extra-cellular matrix (ECM)
- **Easy to use and apply**: Allows multiple quick and easy applications to achieve better outcomes, even in high-risk patients

Patient Impact

Scan the QR code below to hear directly from patient, Victor, sharing his reality of living with RP and his experience following treatment with PuraStat.

“*It’s just getting your life back, that’s what it’s basically about*”

- Victor

Also available on YouTube: [https://bit.ly/3LXCL8c](https://bit.ly/3LXCL8c)
For application within gastroenterology, PuraStat is indicated for:

1. Achieving haemostasis in bleeding from small blood vessels and oozing from capillaries of the GI tract following surgical procedures and surrounding tissues [when haemostasis by ligation or standard means is insufficient or impractical]

2. Reduction of delayed bleeding following gastrointestinal endoscopic submucosal dissection (ESD) procedures in the colon

Available in 1 ml (621-034), 3 ml (621-035) and 5 ml (621-036)

**Clinical Study:**
Endoscopically delivered PuraStat for the treatment of severe haemorrhagic radiation proctopathy: A service evaluation of a new endoscopic treatment for a challenging condition

Henson C., and White K., 2021

**Clinician Video:**
Personal experience sharing of using PuraStat for radiation proctopathy

Dr John Hancock, Consultant Gastroenterologist, North Tees and Hartlepool NHS Foundation Trust

**Case Report:**
Haemostatic properties of PuraStat in radiation proctopathy

Dr Sergio Coda, Consultant Gastroenterologist and Clinical Director of Bowel Screening Programme, Queen’s Hospital, Barking, Havering and Redbridge University

From a patients’ perspective, patients are very reassured since I’ve started using PuraStat. They’ve communicated their improvements to me, [...] particularly regarding the reduction in weekly bleeding episodes.

We’ve also noticed an improvement in haemoglobin levels, resulting in less need and dependence on iron supplementations or transfusions.

**Application Tips for RP**

1. Remove any excess blood/mucus from the site.
2. Position the catheter as close as possible to the bleeding site.
3. Push down on the syringe slowly to apply a thin layer of PuraStat.
4. Use a ‘painting’ or ‘pipetting’ technique* to fully cover the bleeding site.
5. Haemostasis is achieved. Usually 3 treatments are required, in 3-4 week intervals*.

*Based on feedback from healthcare professional users.

**References:**

(1) PuraStat IFU-007 Rev 2

PuraStat is a class III medical device, CE marked according to European council directive 93/42/EEC on medical devices and its relatives

3-D Matrix Europe SAS
11 chemin des Petites Brosses
69300 Caluire-et-Cuire-FRANCE
Tel: +33 (0)4 27 19 03 40
infoeu@puramatrix.com

Please visit for more information:
www.3dmatrix.com

BR MS 014 BU EN v1 2023 05 23